AMSTERDAM, July 5, 2012 /PRNewswire/ -- Leading events organiser UBM Conferences, a division of UBM Plc (LSE: UBM), has announced details for its Generics and Biosimilars Conference to be held in Istanbul from September 18th to 20th at the Hilton Garden Inn Istanbul Golden Horn. The conference will focus on the advantages and challenges of operating in the evolving generics and biosimilars markets including: market potential; how to address pricing; legislative and regulatory hurdles; and the emergence of the EMEA regions including Central and Eastern Europe, the Commonwealth of Independent States (CIS), Turkey and the Middle East.
The three-day programme includes a full agenda of presentations, discussions and workshops that can be found here. Confirmed speakers for the Conference include high profile domestic and global representatives from companies like Merck, Sharpe and Dohme, Teva, Merck Bioventures, Pfizer, Biocad, Novartis, Mylan, Glenmark Generics and more, as well as support from the Bulgarian Generics Pharmaceutical Association, Jordanian Association of Pharmaceutical Manufacturers, the Russian Pharma Licensing Group and the Generics Bulletin.
"This year's event aims to facilitate networking and discussion between global and domestic players who are active in key pharmerging markets," stated Conference Producer, Joel Hornby. "The Economist Intelligence Unit (EIU) forecasts five MENA markets will represent a combined GDP of US $2.5 trillion by 2016, led by Turkey and Saudi Arabia and the IHS Global Insight forecasts continued growth of about 10% in Russia. Now is the time to cultivate business relationships within this market, and the Generics and Biosimilars Conference offers an exceptional platform to do so."
Comprised of executives from business development, product development, sales and marketing, regulatory, scientific research
|SOURCE UBM Conferences|
Copyright©2012 PR Newswire.
All rights reserved